EP2629764A1 - Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose - Google Patents
Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial doseInfo
- Publication number
- EP2629764A1 EP2629764A1 EP11772999.6A EP11772999A EP2629764A1 EP 2629764 A1 EP2629764 A1 EP 2629764A1 EP 11772999 A EP11772999 A EP 11772999A EP 2629764 A1 EP2629764 A1 EP 2629764A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- compound
- product according
- tetracycline
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 239000000945 filler Substances 0.000 title claims abstract description 58
- 239000004098 Tetracycline Substances 0.000 title claims abstract description 42
- 235000019364 tetracycline Nutrition 0.000 title claims abstract description 42
- 150000003522 tetracyclines Chemical class 0.000 title claims abstract description 41
- 229960002180 tetracycline Drugs 0.000 title claims abstract description 38
- 229930101283 tetracycline Natural products 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 239000000047 product Substances 0.000 claims abstract description 55
- 239000013066 combination product Substances 0.000 claims abstract description 24
- 229940127555 combination product Drugs 0.000 claims abstract description 24
- 230000009759 skin aging Effects 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 17
- 231100000241 scar Toxicity 0.000 claims abstract description 17
- 230000037387 scars Effects 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 229920002674 hyaluronan Polymers 0.000 claims description 25
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 23
- 229960003160 hyaluronic acid Drugs 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 17
- 206010040954 Skin wrinkling Diseases 0.000 claims description 15
- 230000037303 wrinkles Effects 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 7
- 229960003722 doxycycline Drugs 0.000 claims description 7
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 229920001059 synthetic polymer Polymers 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 229920002439 Polyalkylimide Polymers 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 229940102223 injectable solution Drugs 0.000 claims description 5
- 239000004005 microsphere Substances 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 229940040944 tetracyclines Drugs 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 3
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229960004989 tetracycline hydrochloride Drugs 0.000 claims description 3
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 claims description 2
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 claims description 2
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- BZUKDLNEDCDORL-ULRSWZSCSA-N C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCN(C)CCN(C)CNC(=O)C=5C([C@@]6(O)C(O)=C7[C@@H]([C@](C8=CC=CC(O)=C8C7=O)(C)O)C[C@H]6[C@@H](C=5O)N(C)C)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCN(C)CCN(C)CNC(=O)C=5C([C@@]6(O)C(O)=C7[C@@H]([C@](C8=CC=CC(O)=C8C7=O)(C)O)C[C@H]6[C@@H](C=5O)N(C)C)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O BZUKDLNEDCDORL-ULRSWZSCSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 239000004100 Oxytetracycline Substances 0.000 claims description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 2
- 229960002398 demeclocycline Drugs 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 229950004798 etamocycline Drugs 0.000 claims description 2
- 229960004196 lymecycline Drugs 0.000 claims description 2
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 claims description 2
- 229960000826 meclocycline Drugs 0.000 claims description 2
- 229940042016 methacycline Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960000625 oxytetracycline Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
- 235000019366 oxytetracycline Nutrition 0.000 claims description 2
- 229960005009 rolitetracycline Drugs 0.000 claims description 2
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004089 tigecycline Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 27
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 13
- 229960004194 lidocaine Drugs 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- -1 sodium alginate Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229960004716 idoxuridine Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229940049501 hyaluronic acid 20 mg/ml Drugs 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000501 collagen implant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001823 Aquamid® Polymers 0.000 description 1
- 108010008457 Artecoll Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920001954 Restylane Polymers 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 108010089886 dermicol-P35 27G Proteins 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108010020199 glutaraldehyde-cross-linked collagen Proteins 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000729 hypotrophic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Definitions
- compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose
- the present invention relates to compositions for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose.
- the invention also relates to the use of these compositions especially for treating skin aging, in particular for treating by filling wrinkles, fine lines, fibroblast depletions, dehydration of the skin and any scars. Skin aging is one of the most visible modifications of the senescence process. In addition, the skin is exposed to many factors capable of accelerating this physiological process.
- the horny layer is relatively unmodified.
- the epidermis is atrophic and the dermal-epidermal junction is flattened, such that the adhesion to the dermis is weaker, facilitating the formation of bubbles.
- the thickness of the dermis is very much reduced; there are fewer blood vessels. Fewer fibroblasts are also observed and their biosynthetic and proliferative capacities are reduced.
- the elastic fibres first undergo modifications, and subsequently disappear.
- Wrinkles are the most visible signs of aging. A distinction can be made between several types, in particular superficial and deep wrinkles. Deep wrinkles appear to be due to dermo-hypodermal modifications, whereas superficial wrinkles could be explained by dermal and possibly epidermal modifications. Wrinkles are especially due to the loss of elasticity of the skin. The collagen present in the dermis fragments, and this fragmentation leads to a loss of structural integrity and also fibroblast dysfunction (Fisher et al, Looking older, Arch Dermatol. 2008; 144(5): 666-672). The damage to the subepidermal elastic network gives rise to superficial laxity of the aged skin and to folding of its surface.
- the destruction of the elastic fibres in the reticular dermis is responsible for the loss of elasticity and of the ability of the skin to return its shape after stretching.
- a suitable treatment will be possible according to the type, the intensity and the topography of the wrinkles.
- the skin contains 20% of all the water contained in the human body and 70% of the water in the skin is concentrated in the dermis. It plays a fundamental role by contributing to the mechanical properties of the dermis and to the physiological functioning of the skin, in particular to the integrity of the skin barrier.
- Hyaluronic acid which is synthesized by the fibroblasts and the keratinocytes, is a major constituent of the extracellular matrix which has an important structural function, which makes it one of the key components for maintaining dermal density and therefore the firmness of the skin.
- recessed scars are pathological; among the latter, mention may be made of recessed scars and raised scars.
- Recessed scars are hypotrophic scars which can be unsightly, more particularly when they affect the face in the case of acne scars.
- Such therapeutic techniques are in particular the local injection of deactivated botulinum toxin (Botox ® ) or the use of laser techniques. These various treatments are not exclusive and combining them has even been recommended.
- Botox ® deactivated botulinum toxin
- dermal implants are used, but none has yet been considered ideal in the context of a safe and healthy tissue augmentation (Naoum C, Dasiou-Plakida D. Dermal filler materials and botulin toxin Int J Dermatol. 2001 Oct; 40 (10): 609-21).
- the inflammation triggered by administration of these implants activates the immune system, in particular through activation of macrophages, resulting in the release of certain mediators and of free radicals which promote degradation of the implants.
- doxycycline and other tetracyclines are normally used for their broad-spectrum antibiotic properties for treating numerous bacterial infections.
- one problem that the invention proposes to solve is that of producing compositions which make it possible to effectively treat skin aging while at the same time substantially reducing the side effects resulting directly or indirectly from the induction of the inflammatory reaction, and increasing the lifespan of the filler products by decreasing the degradation processes directly related to the inflammatory reaction or related to the activation of enzymes involved in the extracellular matrix degradation process (metalloprotease, protease, collagenase, elastase, in particular).
- the present invention makes it possible to prevent and treat skin aging, in particular wrinkles and fine lines, with improved effectiveness and much reduced side effects.
- the subject of the present invention is thus the specific combination of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose.
- Such a combination makes it possible to treat skin aging and scars, in particular by filling, in an effective and safe manner.
- the first subject of the invention is therefore a combination product comprising:
- composition A comprising at least one filler product
- composition B comprising at least one compound of the tetracycline family used at a subantimicrobial dose
- compositions A and B for the treatment of skin aging and scars, compositions A and B being used simultaneously, separately or sequentially over time.
- the term "simultaneously” is intended to mean application of the filler product and of the compound of the tetracycline family used at a subantimicrobial dose at the same time.
- the term "sequentially over time” is intended to mean a consecutive application of each composition, of the filler product and of the compound of the tetracycline family used at a subantimicrobial dose, over a longer period of time (i.e. greater than 1 h and possibly ranging up to one month after injection of the filler product).
- compositions A and B are used simultaneously, and more preferably in one fixed combination product.
- the filler product can therefore be administered to a patient independently, as is the case for composition A of the combination product.
- the filler product is included in a separate composition (composition A of the combination product), which can be administered simultaneously or else at a different time from that of the administration of composition B comprising the compound of the tetracycline family used at a subantimicrobial dose.
- composition A comprising the filler product could be administered topically or parenterally, for example by injection.
- composition A is administered by injection.
- composition B of the combination product comprising the chemically modified tetracycline
- composition B can be administered topically, parenterally or orally.
- composition B is administered by injection or topically.
- composition A is in the form of an injectable solution and composition B is suitable for application by injection or topically.
- compositions A and B are each in the form of an injectable solution, they can be administered by simultaneous coinjection, in particular using a double syringe, or else by injection of each solution one after the other, or using a combination of A and B in one injectable fixed combination product.
- the combination product is preferentially used for the treatment of skin aging, and more preferentially for the treatment of wrinkles and fine lines.
- the subject of the invention is also and preferably a single pharmaceutical composition, in particular for topical and/or parenteral application, comprising, in the same physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose.
- physiologically acceptable medium is intended to mean a medium that is compatible with the skin, the mucous membranes and/or the skin appendages.
- the filler product may also contain another active ingredient, for instance an anaesthetic such as lidocaine.
- an anaesthetic such as lidocaine.
- Said single pharmaceutical composition is preferably intended for the treatment of skin aging and of scars.
- the pharmaceutical composition is intended for the treatment of wrinkles and fine lines.
- skin aging is intended to mean more particularly wrinkles, fine lines, fibroblast depletions and dehydration of the skin.
- This single pharmaceutical composition can be administered topically or parenterally, for example by injection.
- this single pharmaceutical composition is administered by injection.
- this single pharmaceutical composition is administered using a syringe or any other injection device.
- the subject of the present invention is also a kit comprising: - at least one filler product, and
- the kit according to the invention comprises a first composition A comprising at least the filler product, and a second composition B, distinct from the first, comprising the compound of the tetracycline family used at a subantimicrobial dose.
- the two compositions obtained can be packaged together or separately.
- the subject of the invention is also and preferably the fixed combination of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose, for use thereof in the treatment of skin aging and scars.
- the combination product or the single pharmaceutical composition according to the invention comprises at least one filler product.
- filler product is intended to mean any product which, when it is applied in particular by injection to the skin, makes it possible to smooth out said skin. The consistency of said product is therefore more or less thick depending on the depth of the recess to be filled in.
- Said filler product is in particular composed of classical filler compounds well-known by the man skilled in the art of aesthetic dermatology.
- filler compounds according to the invention it is understood collagen and its derivatives, hyaluronic acid, its salts and its derivatives, alginates, synthetic polymers, elastin and biological polymers, and mixtures thereof.
- the filler product comprises filler compounds chosen from collagen of human origin, collagen of porcine origin, collagen of bovine origin, crosslinked collagens, hyaluronic acid, its salts and its derivatives, lactic acid polymers, methacrylate derivatives, calcium phosphate derivatives, polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones, silica (Si0 2 ) polymers and biological polymers, and mixtures thereof.
- Collagen is a fibrous protein, of approximately 300 kDa, which makes up the connective tissue in the animal kingdom. It may be of human or nonhuman origin, in particular of porcine or bovine origin.
- Collagen derivatives include, inter alia, crosslinked collagens. The collagen and derivatives thereof can optionally be mixed with an anaesthetic, such as lidocaine.
- Filler products based on collagen and derivatives thereof are in particular the products:
- Evolence ® from ColBar which is made up of crosslinked porcine collagen.
- the filler product may also comprises filler compounds chosen from an alginate or salts thereof.
- alginate salts such as sodium alginate
- crosslinked alginates for instance the product Novabel ® from Merz Aesthetics.
- the filler product may also comprises filler compounds chosen from a synthetic polymer.
- synthetic polymer is intended to mean a system formed by a collection of macromolecules of the same chemical nature, resulting from the covalent linking of a large number of identical or different monomer units of synthetic origin, prepared by polymerization of monomer molecules.
- said synthetic polymer is chosen from lactic acid polymers such as poly-L-lactic acid, methacrylate derivatives such as hydroxyethyl methacrylate (HEMA), ethyl methacrylate (EMA), or poly(methyl methacrylate) (PMMA), calcium phosphate derivatives (hydroxylapatite or tricalcium phosphate), polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones and silica (Si0 2 ) polymers, and mixtures thereof.
- HEMA hydroxyethyl methacrylate
- EMA ethyl methacrylate
- PMMA poly(methyl methacrylate)
- calcium phosphate derivatives hydroxylapatite or tricalcium phosphate
- polyacrylamides polyurethanes
- polyalkylimide gels polyvinyl microspheres
- silicones and silica (Si0 2 ) polymers and mixtures thereof.
- Artefill ® or Artecoll ® from Artes Medical which is a mixture of PMMA and bovine collagen and lidocaine;
- Bio-Alcamid ® from SkinRx Distribution Inc. which is a polyalkylimide gel
- the filler product may also comprises filler compounds chosen from a biological polymer.
- biological polymer is intended to mean a system formed by a collection of macromolecules of the same chemical nature, resulting from the covalent linking of a large number of identical or different monomer units of natural origin or artificial origin (obtained by chemical modification of a natural polymer).
- said biological polymer is chosen from polymers of methylcellulose, of agarose, of dextran or of chitosan.
- Filler products based on biological polymers are in particular the products:
- Reviderm Intra ® from Rofil Medical International which is a dextran polymer.
- the filler product comprises filler compounds chosen from hyaluronic acid, a pharmaceutically acceptable salt thereof or a derivative, particularly a sodium or potassium salt.
- Hyaluronic acid can be used in various forms: a salt, a derivative such as an ester or an amide, or in linear or crosslinked form.
- the molecular weight is conventionally between 500 kDa and 5000 kDa and the degree of crosslinking depends on the use and the site of application, especially in the wrinkle field.
- Hyaluronic acid is a ubiquitous natural polysaccharide which exists in the same form from the simplest bacterium to humans. It is a polysaccharide composed alternately of D-glucuronic acid and N- acetylglucosamine, linked to one another by alternating beta-1,4 and beta-1,3 glycosidic linkages. According to Saari H et al.
- the polymers of this recurring unit may be between 10 2 and 10 4 kDa in size, in vivo, hyaluronic acid taken from the umbilical cord having a weight of 2500 kDa.
- Hyaluronic acid represents a natural constituent of the dermis, where it plays an important role in the hydration and elasticity of the skin. However, it decreases in amount and in quality with age, leading to drying out of the skin, which becomes wrinkled. It is highly water-soluble and forms high-viscosity solutions in water. The tolerance of hyaluronic acid is very good and no immunogenicity has been associated with this substance.
- the hyaluronic acid may be of human or nonhuman origin, for instance of avian or bacterial origin.
- pharmaceutically acceptable salt is intended to mean a basic or acidic salt, such as, by way of nonlimiting examples, hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate, bisulphate, phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and pamoate (i.e., l, l'-methylenebis(2-hydroxy-3-naphthoate)), salts, aluminium, calcium, lithium, magnesium, potassium, sodium, zinc, or diethanolamine salts.
- Certain compounds according to the invention can form pharmaceutically acceptable salt
- the hyaluronic acid may also be combined in the filler product with at least one dextran, in order to slow down its degradation in vivo.
- Filler products based on hyaluronic acid and derivatives thereof are in particular the products:
- EMERVEL® a complete range of nine scientifically-advanced and clinically-proven hyaluronic acid dermal fillers, also available with the local anaesthetic lidocaine;
- Hylaform ® , Hylaform Plus ® or Captique ® from Genzyme/Allergan, which are chemically modified hyaluronic acids of avian origin; Elevess R from Anika, which is composed of hyaluronic acid of Streptococcus bacteria mixed with lidocaine; or else
- Matridex ® from TBMC Aesthetics which is a gel composed of hyaluronic acid combined with dextran beads (DEAE Sephadex).
- the combination product or the single pharmaceutical composition according to the invention also comprises at least one compound of the tetracycline family used at a subantimicrobial dose.
- the tetracyclines according to the invention are natural or semisynthetic tetracycline compounds obtained from tetracycline, used at a subantimicrobial dose.
- subantimicrobial dose is intended to mean a dose which is less than that which makes it possible to have an antibiotic activity.
- Tetracycline is an antibiotic having the following formula:
- compound of the tetracycline family is intended to mean more particularly natural or semisynthetic tetracyclines, such as doxycycline, minocycline, tetracycline, tetracycline hydrochloride, oxytetracycline, chlorotetracycline, demeclocycline, etamocycline, rolitetracycline, metacycline, lymecycline, meclocycline and tigecycline.
- compositions according to the invention is intended to mean compositions A and B or else the single pharmaceutical compositions, or the fixed combination composition containing both the filler product and the compound of the tetracycline family used at a subantimicrobial dose.
- the filler compound present in the filler product is present in proportions that can range from 0.001% to 10% by weight, relative to the total weight of the composition, preferentially from 0.1% to 5% of filler product, more preferably from 1.5% to 2.5% by weight, relative to the total weight of the composition.
- the chemically modified tetracycline is present in proportions that can range from 0.01% to 5% by weight, relative to the total weight of the composition, more preferably from 0.02% to 0.03% by weight, relative to the total weight of the composition.
- the composition according to the invention is an injectable fixed combination composition.
- the composition comprises a filler composed of Hyaluronic acid, in proportions that can range from 1 to 3 % by weight, relative to the total weight of the composition, preferentially from 1.5% to 2.5% , more preferable from 2 to 2.5% and from 0.01% to 5% of chemically modified tetracycline, preferably from 0.02 to 0.03 % by weight, relative to the total weight of the composition, in a physiological vehicle.
- the vehicle is preferably a physiological buffer, chosen from water, saline solution, phosphate buffer. According to the invention physiological buffer leads to a physiological pH of the composition, which can range from pH 6 to pH 8 and more preferable to pH 7.
- ranges of hyaluronic acid are also expressed in weight relative to total volume of the composition.
- the composition comprises a filler composed of Hyaluronic acid, in proportions that can range from 15 to 30 mg per ml of the total composition, preferentially from 15 to 25mg/ml , more preferably from 20 to 25 mg/ml and from 1 to 5 mg/ml of chemically modified tetracycline, preferably from 2 to 3mg/ml of the total volume of the composition, in a physiological vehicle.
- the composition is a composition having a total volume comprised between 0.8 and 5ml, preferably 1 or 2 ml.
- compositions according to the invention may also contain the usual adjuvants well known to those skilled in the art.
- topically is intended to mean external application to the skin or the mucous membranes.
- compositions can be in any of the galenic forms normally used for topical administration.
- topical compositions mention may be made of compositions in liquid, pasty or solid form, and more particularly in the form of salves, aqueous, aqueous-alcoholic or oily solutions, dispersions of the lotion type, which optionally have two-phases, sera, aqueous, anhydrous or lipophilic gels, powders, impregnated pads, syndets, wipes, sprays, foams, sticks, compresses, washing bases, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice versa (W/O), a microemulsion, suspensions or emulsions of soft, semi-liquid or solid consistency of the cream or ointment type, suspensions of microspheres or nanospheres or lipid or polymeric vesicles, or microcapsule
- parenterally is intended to mean subcutaneous or intradermal application.
- parenteral compositions mention may be made of compositions in the form of solutions or suspensions for infusion or for injection.
- the compositions may be administered using conventional syringes or double syringes (where two compositions are separated from one another by a leaktight membrane, and where the mixing takes place as the compositions leave the syringe).
- the administration frequencies may be identical or different.
- the frequency of administration of composition A injected in the form of an injectable solution can range from 4 to 24 months, preferentially from 4 to 16 months
- those of composition B according to the invention, administered topically, for example in the form of a cream can range from 1 to 30 days, preferentially from 1 to 7 days.
- the invention relates to the use of at least one filler product and at least one chemically modified tetracycline, in a fixed combination product, for producing a pharmaceutical composition intended for the treatment of skin aging and of scars.
- the composition according to the invention is suitable for the treatment of wrinkled and/or aged skin, and is aimed in particular at preventing and/or reducing the effects thereof.
- the treatment of wrinkles, fine lines, fibroblast depletions, dehydration of the skin and any scars is carried out in particular by filling-in.
- the composition according to the invention can be applied to the skin of the face and of the body.
- composition according to the invention can be applied to the areas of the face or of the forehead that are marked by expression wrinkles or by scars, inter alia due to acne.
- the invention also relates to the use of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose, preferably of a single pharmaceutical composition as described above or of a combination product, for producing a pharmaceutical composition intended to be used in reconstructive surgery.
- Example 1 Fixed combination composition according to the invention.
- Example 2 Fixed combination composition according to the invention
- Example 3 Fixed combination composition according to the invention
- Example 4 Fixed combination composition according to the invention
- Example 5 Fixed combination composition according to the invention
- Example 6 Fixed combination composition according to the invention
- Example 6 Fixed combination composition according to the invention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a combination product comprising: a composition A comprising at least one filler product, and a composition B comprising at least one compound of the tetracycline family used at a subantimicrobial dose, for the treatment of skin aging and scars, compositions A and B being used simultaneously, separately or sequentially over time. The invention also relates to a single pharmaceutical composition comprising, in the same physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose.
Description
Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose
The present invention relates to compositions for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose. The invention also relates to the use of these compositions especially for treating skin aging, in particular for treating by filling wrinkles, fine lines, fibroblast depletions, dehydration of the skin and any scars. Skin aging is one of the most visible modifications of the senescence process. In addition, the skin is exposed to many factors capable of accelerating this physiological process.
A distinction is made between two different types of skin aging. Firstly, intrinsic (or physiological) aging, which is evaluated more easily on areas of skin that are not normally exposed to the sun, and, secondly, extrinsic aging caused by the interaction of environmental factors, in particular UV rays. These environmental factors have a much more marked effect on the parts of the body exposed to the sun, especially in individuals with a fair phototype. The term actinic aging is then also used. Other factors, such as dietary habits, smoking, excessive alcohol consumption, chronic diseases and endocrine gland dysfunctions, also contribute to this aging.
During intrinsic skin aging, the horny layer is relatively unmodified. The epidermis is atrophic and the dermal-epidermal junction is flattened, such that the adhesion to the dermis is weaker, facilitating the formation of bubbles. The thickness of the dermis is very much reduced; there are fewer blood vessels. Fewer fibroblasts are also observed and their biosynthetic and proliferative capacities are reduced. The elastic fibres first undergo modifications, and subsequently disappear.
As regards extrinsic aging, an irregular, sometimes atrophic, sometimes hyperplastic, epidermis is observed, with signs of disorganization and of dysplasia. There are more melanocytes in certain areas, and fewer in others. The distribution of melanin in the epidermis is also irregular, subsequent to melanosome transfer problems. The number of Langerhans cells decreases. The small blood vessels are first dilated, and then become thinner and atrophy.
Wrinkles are the most visible signs of aging. A distinction can be made between several types, in particular superficial and deep wrinkles. Deep wrinkles appear to be due to dermo-hypodermal modifications, whereas superficial wrinkles could be explained by dermal and possibly epidermal modifications. Wrinkles are especially due to the loss of elasticity of the skin. The collagen present in the dermis fragments, and this fragmentation leads to a loss of structural integrity and also fibroblast dysfunction (Fisher et al, Looking older, Arch Dermatol. 2008; 144(5): 666-672). The damage to the
subepidermal elastic network gives rise to superficial laxity of the aged skin and to folding of its surface. The destruction of the elastic fibres in the reticular dermis is responsible for the loss of elasticity and of the ability of the skin to return its shape after stretching. A suitable treatment will be possible according to the type, the intensity and the topography of the wrinkles. The skin contains 20% of all the water contained in the human body and 70% of the water in the skin is concentrated in the dermis. It plays a fundamental role by contributing to the mechanical properties of the dermis and to the physiological functioning of the skin, in particular to the integrity of the skin barrier. Hyaluronic acid, which is synthesized by the fibroblasts and the keratinocytes, is a major constituent of the extracellular matrix which has an important structural function, which makes it one of the key components for maintaining dermal density and therefore the firmness of the skin. It is also a real water sponge essential for maintaining hydration. The synthesis and the quality of hyaluronic acid decreases over the years, causing dehydration, sagging and loss of firmness of the skin. It is therefore essential to maintain a good level of hydration of the skin, in order to limit skin aging.
Some scars are pathological; among the latter, mention may be made of recessed scars and raised scars. Recessed scars are hypotrophic scars which can be unsightly, more particularly when they affect the face in the case of acne scars.
Over the past few years, there has been an enormous amount of progress in the treatment of unsightly skin modifications related to aging and to scars. A relatively large number of natural or synthetic substances have already been described as dermal implants, i.e. as substances injected directly into the skin, in order to remedy skin modifications resulting from aging, from trauma or from diseases.
Such therapeutic techniques are in particular the local injection of deactivated botulinum toxin (Botox®) or the use of laser techniques. These various treatments are not exclusive and combining them has even been recommended. Currently, many dermal implants are used, but none has yet been considered ideal in the context of a safe and healthy tissue augmentation (Naoum C, Dasiou-Plakida D. Dermal filler materials and botulin toxin Int J Dermatol. 2001 Oct; 40 (10): 609-21).
Moreover, many side effects of these implants have been observed, such as haematomas, erythema, oedema (which can occur rapidly, i.e. within a day or week following application of the product); infections and inflammations (semi-delayed side effects, occurring within 1 to 3 weeks following application of the product); or else allergies or pigmentations of the skin as a reaction to the product.
Indeed, the inflammation triggered by administration of these implants activates the immune system, in particular through activation of macrophages, resulting in the release of certain mediators and of free radicals which promote degradation of the implants.
Conventionally, doxycycline and other tetracyclines are normally used for their broad-spectrum antibiotic properties for treating numerous bacterial infections.
Given the aforementioned, one problem that the invention proposes to solve is that of producing compositions which make it possible to effectively treat skin aging while at the same time substantially reducing the side effects resulting directly or indirectly from the induction of the inflammatory reaction, and increasing the lifespan of the filler products by decreasing the degradation processes directly related to the inflammatory reaction or related to the activation of enzymes involved in the extracellular matrix degradation process (metalloprotease, protease, collagenase, elastase, in particular).
The present invention makes it possible to prevent and treat skin aging, in particular wrinkles and fine lines, with improved effectiveness and much reduced side effects.
The subject of the present invention is thus the specific combination of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose. Such a combination makes it possible to treat skin aging and scars, in particular by filling, in an effective and safe manner.
The first subject of the invention is therefore a combination product comprising:
- a composition A comprising at least one filler product, and
- a composition B comprising at least one compound of the tetracycline family used at a subantimicrobial dose,
for the treatment of skin aging and scars, compositions A and B being used simultaneously, separately or sequentially over time. The term "simultaneously" is intended to mean application of the filler product and of the compound of the tetracycline family used at a subantimicrobial dose at the same time.
The term "separately" is intended to mean the consecutive application of each composition, of the filler product and of the compound of the tetracycline family used at a subantimicrobial dose, over a short period of time (i.e. less than or equal to 1 h).
The term "sequentially over time" is intended to mean a consecutive application of each composition, of the filler product and of the compound of the tetracycline family used at a subantimicrobial dose, over a longer period of time (i.e. greater than 1 h and possibly ranging up to one month after injection of the filler product).
Preferably according to the invention, the compositions A and B are used simultaneously, and more preferably in one fixed combination product.
The filler product can therefore be administered to a patient independently, as is the case for composition A of the combination product. In this case, the filler product is included in a separate composition (composition A of the combination product), which can be administered simultaneously or else at a different time from that of the administration of composition B comprising the compound of the tetracycline family used at a subantimicrobial dose.
Composition A comprising the filler product could be administered topically or parenterally, for example by injection. Preferably, composition A is administered by injection.
Composition B of the combination product, comprising the chemically modified tetracycline, can be administered topically, parenterally or orally. Preferably, composition B is administered by injection or topically.
Preferably, composition A is in the form of an injectable solution and composition B is suitable for application by injection or topically. When compositions A and B are each in the form of an injectable solution, they can be administered by simultaneous coinjection, in particular using a double syringe, or else by injection of each solution one after the other, or using a combination of A and B in one injectable fixed combination product.
The combination product is preferentially used for the treatment of skin aging, and more preferentially for the treatment of wrinkles and fine lines.
The subject of the invention is also and preferably a single pharmaceutical composition, in particular for topical and/or parenteral application, comprising, in the same physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose. The term "physiologically acceptable medium" is intended to mean a medium that is compatible with the skin, the mucous membranes and/or the skin appendages.
The filler product may also contain another active ingredient, for instance an anaesthetic such as lidocaine.
Said single pharmaceutical composition is preferably intended for the treatment of skin aging and of scars. Preferentially, the pharmaceutical composition is intended for the treatment of wrinkles and fine lines. The term "skin aging" is intended to mean more particularly wrinkles, fine lines, fibroblast depletions and dehydration of the skin.
This single pharmaceutical composition can be administered topically or parenterally, for example by injection. Preferably, this single pharmaceutical composition is administered by injection. Preferably, this single pharmaceutical composition is administered using a syringe or any other injection device.
The subject of the present invention is also a kit comprising:
- at least one filler product, and
- at least one compound of the tetracycline family used at a subantimicrobial dose.
The kit according to the invention comprises a first composition A comprising at least the filler product, and a second composition B, distinct from the first, comprising the compound of the tetracycline family used at a subantimicrobial dose. The two compositions obtained can be packaged together or separately.
The subject of the invention is also and preferably the fixed combination of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose, for use thereof in the treatment of skin aging and scars.
The combination product or the single pharmaceutical composition according to the invention comprises at least one filler product. The term "filler product" is intended to mean any product which, when it is applied in particular by injection to the skin, makes it possible to smooth out said skin. The consistency of said product is therefore more or less thick depending on the depth of the recess to be filled in.
Said filler product is in particular composed of classical filler compounds well-known by the man skilled in the art of aesthetic dermatology. By filler compounds according to the invention, it is understood collagen and its derivatives, hyaluronic acid, its salts and its derivatives, alginates, synthetic polymers, elastin and biological polymers, and mixtures thereof.
Preferably, the filler product comprises filler compounds chosen from collagen of human origin, collagen of porcine origin, collagen of bovine origin, crosslinked collagens, hyaluronic acid, its salts and its derivatives, lactic acid polymers, methacrylate derivatives, calcium phosphate derivatives, polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones, silica (Si02) polymers and biological polymers, and mixtures thereof. Collagen is a fibrous protein, of approximately 300 kDa, which makes up the connective tissue in the animal kingdom. It may be of human or nonhuman origin, in particular of porcine or bovine origin. Collagen derivatives include, inter alia, crosslinked collagens. The collagen and derivatives thereof can optionally be mixed with an anaesthetic, such as lidocaine.
Filler products based on collagen and derivatives thereof are in particular the products:
- Cosmoderm® and Cosmoplast® from Inamed/Allergan, which are purified human collagens mixed with lidocaine;
Zyderm" and Zyplast" from Inamed/Allergan, which are highly purified bovine collagens mixed with lidocaine; or else
Evolence® from ColBar, which is made up of crosslinked porcine collagen. The filler product may also comprises filler compounds chosen from an alginate or salts thereof. Among the alginates that can be used, mention may be made of alginate salts, such as sodium alginate, or else crosslinked alginates, for instance the product Novabel® from Merz Aesthetics.
The filler product may also comprises filler compounds chosen from a synthetic polymer. The term "synthetic polymer" is intended to mean a system formed by a collection of macromolecules of the same chemical nature, resulting from the covalent linking of a large number of identical or different monomer units of synthetic origin, prepared by polymerization of monomer molecules. Preferably, said synthetic polymer is chosen from lactic acid polymers such as poly-L-lactic acid, methacrylate derivatives such as hydroxyethyl methacrylate (HEMA), ethyl methacrylate (EMA), or poly(methyl methacrylate) (PMMA), calcium phosphate derivatives (hydroxylapatite or tricalcium phosphate), polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones and silica (Si02) polymers, and mixtures thereof. Filler products based on synthetic polymers are in particular the products:
Sculptra® from Dermik, which is a synthetic polymer of lactic acid;
Artefill® or Artecoll® from Artes Medical, which is a mixture of PMMA and bovine collagen and lidocaine;
Radiesse® from BioForm, which is calcium hydroxyapatite;
Beta-Altean® from Stiefel, which is tricalcium phosphate;
Bio-Alcamid® from SkinRx Distribution Inc., which is a polyalkylimide gel,
Evolution® from Procytech SA, which is polyvinyl microspheres, or else
- Aquamid® from Ferrosan A/S/Contura, which is a polyacrylamide gel.
The filler product may also comprises filler compounds chosen from a biological polymer. The term "biological polymer" is intended to mean a system formed by a collection of macromolecules of the same chemical nature, resulting from the covalent linking of a large number of identical or different monomer units of natural origin or artificial origin (obtained by chemical modification of a natural polymer). Preferably, said biological polymer is chosen from polymers of methylcellulose, of agarose, of dextran or of chitosan.
Filler products based on biological polymers are in particular the products:
Reviderm Intra® from Rofil Medical International, which is a dextran polymer.
More preferentially, the filler product comprises filler compounds chosen from hyaluronic acid, a pharmaceutically acceptable salt thereof or a derivative, particularly a sodium or potassium salt.
Hyaluronic acid can be used in various forms: a salt, a derivative such as an ester or an amide, or in linear or crosslinked form. In particular, the molecular weight is conventionally between 500 kDa and 5000 kDa and the degree of crosslinking depends on the use and the site of application, especially in the wrinkle field.
Hyaluronic acid is a ubiquitous natural polysaccharide which exists in the same form from the simplest bacterium to humans. It is a polysaccharide composed alternately of D-glucuronic acid and N- acetylglucosamine, linked to one another by alternating beta-1,4 and beta-1,3 glycosidic linkages. According to Saari H et al. (Differential effects of reactive oxygen species on native synovial fluid and purified human umbilical cord hyaluronate, Inflammation 17 (1993): 403-415), the polymers of this recurring unit may be between 102 and 104 kDa in size, in vivo, hyaluronic acid taken from the umbilical cord having a weight of 2500 kDa.
Hyaluronic acid represents a natural constituent of the dermis, where it plays an important role in the hydration and elasticity of the skin. However, it decreases in amount and in quality with age, leading to drying out of the skin, which becomes wrinkled. It is highly water-soluble and forms high-viscosity solutions in water. The tolerance of hyaluronic acid is very good and no immunogenicity has been associated with this substance.
The hyaluronic acid may be of human or nonhuman origin, for instance of avian or bacterial origin.
The term "pharmaceutically acceptable salt" is intended to mean a basic or acidic salt, such as, by way of nonlimiting examples, hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate, bisulphate, phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and pamoate (i.e., l, l'-methylenebis(2-hydroxy-3-naphthoate)), salts, aluminium, calcium, lithium, magnesium, potassium, sodium, zinc, or diethanolamine salts. Certain compounds according to the invention can form pharmaceutically acceptable salts with various amino acids (Berge et al, 66 J. Pharm. Sci. 1-19 (1977)).
The hyaluronic acid may also be combined in the filler product with at least one dextran, in order to slow down its degradation in vivo.
Filler products based on hyaluronic acid and derivatives thereof are in particular the products:
EMERVEL®, a complete range of nine scientifically-advanced and clinically-proven hyaluronic acid dermal fillers, also available with the local anaesthetic lidocaine;
Restylane® and Perlane® from Q-Med/Galderma, or Juvederm® from Allergan/Corneal, or Prevelle Silk® from Genzyme, which are hyaluronic acids of Streptococcus bacteria;
Hylaform®, Hylaform Plus® or Captique® from Genzyme/Allergan, which are chemically modified hyaluronic acids of avian origin;
Elevess R from Anika, which is composed of hyaluronic acid of Streptococcus bacteria mixed with lidocaine; or else
Matridex® from TBMC Aesthetics, which is a gel composed of hyaluronic acid combined with dextran beads (DEAE Sephadex).
The combination product or the single pharmaceutical composition according to the invention also comprises at least one compound of the tetracycline family used at a subantimicrobial dose.
The tetracyclines according to the invention are natural or semisynthetic tetracycline compounds obtained from tetracycline, used at a subantimicrobial dose.
The term "subantimicrobial dose" is intended to mean a dose which is less than that which makes it possible to have an antibiotic activity.
Tetracycline is an antibiotic having the following formula:
The carbons on the tetracycline nucleus are numbered as follows:
The term "compound of the tetracycline family" is intended to mean more particularly natural or semisynthetic tetracyclines, such as doxycycline, minocycline, tetracycline, tetracycline hydrochloride, oxytetracycline, chlorotetracycline, demeclocycline, etamocycline, rolitetracycline, metacycline, lymecycline, meclocycline and tigecycline. In the present description, and unless otherwise specified, it is understood that the term "compositions according to the invention" is intended to mean compositions A and B or else the single pharmaceutical compositions, or the fixed combination composition containing both the filler product and the compound of the tetracycline family used at a subantimicrobial dose.
In the compositions according to the invention, the filler compound present in the filler product is present in proportions that can range from 0.001% to 10% by weight, relative to the total weight of the composition, preferentially from 0.1% to 5% of filler product, more preferably from 1.5% to 2.5% by weight, relative to the total weight of the composition.
In the compositions according to the invention, the chemically modified tetracycline is present in proportions that can range from 0.01% to 5% by weight, relative to the total weight of the composition, more preferably from 0.02% to 0.03% by weight, relative to the total weight of the composition.
In one preferred embodiment, the composition according to the invention is an injectable fixed combination composition. Preferably, the composition comprises a filler composed of Hyaluronic acid, in proportions that can range from 1 to 3 % by weight, relative to the total weight of the composition, preferentially from 1.5% to 2.5% , more preferable from 2 to 2.5% and from 0.01% to 5% of chemically modified tetracycline, preferably from 0.02 to 0.03 % by weight, relative to the total weight of the composition, in a physiological vehicle. The vehicle is preferably a physiological buffer, chosen from water, saline solution, phosphate buffer. According to the invention physiological buffer leads to a physiological pH of the composition, which can range from pH 6 to pH 8 and more preferable to pH 7.
In the preferred case of the injectable fixed combination composition, ranges of hyaluronic acid are also expressed in weight relative to total volume of the composition. Preferably, the composition comprises a filler composed of Hyaluronic acid, in proportions that can range from 15 to 30 mg per ml of the total composition, preferentially from 15 to 25mg/ml , more preferably from 20 to 25 mg/ml and from 1 to 5 mg/ml of chemically modified tetracycline, preferably from 2 to 3mg/ml of the total volume of the composition, in a physiological vehicle.
In the preferred case of injectable fixed combination composition, the composition is a composition having a total volume comprised between 0.8 and 5ml, preferably 1 or 2 ml.
In the present description, and unless otherwise specified, it is understood that, when concentration ranges are given, they include the upper and lower limits of said range.
In a known manner, the compositions according to the invention may also contain the usual adjuvants well known to those skilled in the art.
The term "topically" is intended to mean external application to the skin or the mucous membranes.
Topically, the compositions can be in any of the galenic forms normally used for topical administration. By way of nonlimiting example of topical compositions, mention may be made of compositions in liquid, pasty or solid form, and more particularly in the form of salves, aqueous, aqueous-alcoholic or oily solutions, dispersions of the lotion type, which optionally have two-phases, sera, aqueous, anhydrous or lipophilic gels, powders, impregnated pads, syndets, wipes, sprays, foams, sticks, compresses, washing
bases, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice versa (W/O), a microemulsion, suspensions or emulsions of soft, semi-liquid or solid consistency of the cream or ointment type, suspensions of microspheres or nanospheres or lipid or polymeric vesicles, or microcapsules, microparticles or nanoparticles or polymeric or gel patches for controlled release.
The term "parenterally" is intended to mean subcutaneous or intradermal application. By way of nonlimiting examples of parenteral compositions, mention may be made of compositions in the form of solutions or suspensions for infusion or for injection. Parenterally, the compositions may be administered using conventional syringes or double syringes (where two compositions are separated from one another by a leaktight membrane, and where the mixing takes place as the compositions leave the syringe).
In the context of a combined administration of the filler product and of the compound of the tetracycline family according to the invention, the administration frequencies may be identical or different. Advantageously, in the context of the invention, the frequency of administration of composition A injected in the form of an injectable solution can range from 4 to 24 months, preferentially from 4 to 16 months, whereas those of composition B according to the invention, administered topically, for example in the form of a cream, can range from 1 to 30 days, preferentially from 1 to 7 days. More preferably the invention relates to the use of at least one filler product and at least one chemically modified tetracycline, in a fixed combination product, for producing a pharmaceutical composition intended for the treatment of skin aging and of scars.
The composition according to the invention is suitable for the treatment of wrinkled and/or aged skin, and is aimed in particular at preventing and/or reducing the effects thereof. The treatment of wrinkles, fine lines, fibroblast depletions, dehydration of the skin and any scars is carried out in particular by filling-in. The composition according to the invention can be applied to the skin of the face and of the body.
In particular, the composition according to the invention can be applied to the areas of the face or of the forehead that are marked by expression wrinkles or by scars, inter alia due to acne.
The invention also relates to the use of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose, preferably of a single pharmaceutical composition as described above or of a combination product, for producing a pharmaceutical composition intended to be used in reconstructive surgery.
The present invention will now be illustrated by means of the following examples.
Example 1 : Fixed combination composition according to the invention.
Component Concentration (mg/ml)
Hyaluronic acid 20mg/ml
Doxycycline 3 mg/ml
Physiological Buffer Qs 1ml
Example 2 : Fixed combination composition according to the invention
Component Concentration (mg/ml)
Hyaluronic acid 20mg/ml
Lidocaine 3 mg/ml
Minocycline 3 mg/ml
Physiological Buffer Qs 1ml
Example 3 : Fixed combination composition according to the invention
Component Concentration (mg/ml)
Hyaluronic acid 25 mg/ml
Lidocaine 3 mg/ml
Doxycycline 2 mg/ml
Physiological Buffer Qs 1ml
Example 4 : Fixed combination composition according to the invention
Component Concentration (mg/ml)
Hyaluronic acid 20mg/ml
Lidocaine 3 mg/ml
Tetracycline hydrochloride 1.5 mg/ml
Physiological Buffer Qs 1ml
Example 5 : Fixed combination composition according to the invention
Component Concentration (%)
Hyaluronic acid 2%
Lidocaine 0.03%
Doxycycline 0.03%
Physiological Buffer Qs 100
Example 6 : Fixed combination composition according to the invention
Component Concentration (%)
Collagen 2.5%
Lidocaine 0.03%
Doxycycline 0.03%
Physiological Buffer Qs 100
Example 6 : Fixed combination composition according to the invention
Component Concentration (%)
Poly-L-lactic acid 2.5%
Lidocaine 0.03%
Minocycline 0.03%
Physiological Buffer Qs 100
Claims
1. Combination product comprising:
- a composition A comprising at least one filler product, and
- a composition B comprising at least one compound of the tetracycline family used at a subantimicrobial dose,
for the treatment of skin aging and scars, compositions A and B being used simultaneously, separately or sequentially over time.
2. Combination product according to Claim 1, for the treatment of skin aging.
3. Combination product according to Claim 1 or 2, characterized in that composition A is in the form of an injectable solution and composition B is suitable for topical application.
4. Combination product according to Claim 1, characterized in that composition A and composition B are in the form of an injectable solution.
5. Combination product according to claim 1 characterized in that composition A and composition B are in the form of a single pharmaceutical composition comprising, in the same physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose.
6. Combination product according to claim 4 characterized in that composition A and composition B are in the form of a fixed combination composition comprising, in the same physiologically acceptable medium, at least one filler product and at least one chemically modified tetracycline.
7. Combination product according to one of Claims 1 to 6, characterized in that the filler product comprises collagen and its derivatives, hyaluronic acid, its salts and its derivatives, alginates and their salts, synthetic polymers, elastin and biological polymers, and mixtures thereof.
8. Combination product according to one of Claims 1 to 7, characterized in that the filler product is chosen from collagen of human origin, collagen of porcine origin, collagen of bovine origin, crosslinked collagens, hyaluronic acid and its derivatives, alginate salts, crosslinked alginates, lactic acid polymers, methacrylate derivatives, calcium phosphate derivatives, polyacrylamides, polyurethanes, polyalkylimide gels, polyvinyl microspheres, silicones, silica (Si02) polymers, polymers of methylcellulose, of agarose, of dextran or of chitosan, and mixtures thereof.
9. Combination product according to one of Claims 1 to 8, characterized in that the compound of the tetracycline family is chosen from natural or semisynthetic tetracyclines.
10. Combination product according to one of Claims 1 to 9, characterized in that the compound of the tetracycline family is chosen from doxycycline, minocycline, tetracycline, tetracycline hydrochloride, oxytetracycline, chlorotetracycline, demeclocycline, etamocycline, rolitetracycline, metacycline, lymecycline, meclocycline and tigecycline.
11. Combination product according to one of Claims 1 to 10, for use thereof in treating skin aging.
12. Combination product according to one of Claims 1 to 11, characterized in that the treatment of skin aging comprises the treatment of wrinkles, fine lines, fibroblast depletions and dehydration of the skin.
13. Kit comprising :
- a first composition A comprising at least the filler product, and
- a second composition B, distinct from the first, comprising the compound of the tetracycline family used at a subantimicrobial dose.
14. Combination of at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose, for use thereof in the treatment of skin aging and scars.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34484610P | 2010-10-22 | 2010-10-22 | |
| FR1058649A FR2966349B1 (en) | 2010-10-22 | 2010-10-22 | COMPOSITIONS COMPRISING A WRINKLE FILLER AND A TETRACYCLIN FAMILY COMPOUND USED FOR SUB-ANTIMICROBIAL DOSE |
| PCT/EP2011/068517 WO2012052563A1 (en) | 2010-10-22 | 2011-10-24 | Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2629764A1 true EP2629764A1 (en) | 2013-08-28 |
Family
ID=44059058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP11772999.6A Withdrawn EP2629764A1 (en) | 2010-10-22 | 2011-10-24 | Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140148417A1 (en) |
| EP (1) | EP2629764A1 (en) |
| JP (1) | JP2013540147A (en) |
| BR (1) | BR112013009782A2 (en) |
| CA (1) | CA2815299A1 (en) |
| FR (1) | FR2966349B1 (en) |
| WO (1) | WO2012052563A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12491198B2 (en) | 2020-05-11 | 2025-12-09 | Lkf21, Llc | Doxycycline injection for sclerotherapy of lower eyelid festoons and malar edema |
| US20260027038A1 (en) | 2024-07-29 | 2026-01-29 | Allergan Sales, Llc | Topical Skin Care Compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203008A1 (en) * | 1997-01-13 | 2003-10-30 | Subramanian Gunasekaran | Preparation of collagen |
| US20030082120A1 (en) * | 2001-10-26 | 2003-05-01 | Milstein Harold J. | Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family |
| US20070067045A1 (en) * | 2005-09-19 | 2007-03-22 | Ar2 Partners, Inc. | Systems and methods for skin wrinkle removal |
| WO2008121447A1 (en) * | 2007-02-14 | 2008-10-09 | Northwestern University | Self-assembling membranes and related methods thereof |
-
2010
- 2010-10-22 FR FR1058649A patent/FR2966349B1/en not_active Expired - Fee Related
-
2011
- 2011-10-24 BR BR112013009782A patent/BR112013009782A2/en not_active IP Right Cessation
- 2011-10-24 EP EP11772999.6A patent/EP2629764A1/en not_active Withdrawn
- 2011-10-24 US US13/880,945 patent/US20140148417A1/en not_active Abandoned
- 2011-10-24 JP JP2013534344A patent/JP2013540147A/en active Pending
- 2011-10-24 WO PCT/EP2011/068517 patent/WO2012052563A1/en not_active Ceased
- 2011-10-24 CA CA2815299A patent/CA2815299A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| "Martindale: The Complete Drug Reference", 15 January 2014, PHARMACEUTICAL PRESS, London, article ANONYMOUS: "Doxycycline", pages: 1 - 13, XP055205712 * |
| "Martindale: The Complete Drug Reference", 15 January 2014, PHARMACEUTICAL PRESS, London, article ANONYMOUS: "Tetracycline", pages: 1 - 20, XP055205714 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140148417A1 (en) | 2014-05-29 |
| CA2815299A1 (en) | 2012-04-26 |
| BR112013009782A2 (en) | 2016-07-19 |
| FR2966349A1 (en) | 2012-04-27 |
| JP2013540147A (en) | 2013-10-31 |
| FR2966349B1 (en) | 2012-11-09 |
| WO2012052563A1 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5642388B2 (en) | Hyaluronic acid gel graft mixture for injection | |
| RU2740454C2 (en) | Dermal filler compositions, including antioxidants | |
| CN104105474B (en) | Dermal filler composition for fine line treatment | |
| US20100298259A1 (en) | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same | |
| US20100323985A1 (en) | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same | |
| JP6827108B2 (en) | Coacervate Hyaluronan Hydrogel for Dermal Fillers Applications | |
| US20140065221A1 (en) | Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material | |
| WO2014044808A2 (en) | Fast-penetration cosmetic dermal filler for topical application | |
| EP2906193B1 (en) | Modified hyaluronic acid derivatives and use thereof | |
| WO2012052562A1 (en) | Compositions comprising a filler product and a chemically modified tetracycline | |
| US20100323983A1 (en) | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof, and uses thereof | |
| KR20230065274A (en) | Tissue-Derived Matrikin Compositions and Methods Thereof | |
| JP2024144774A (en) | Cosmetic/dermatological compositions | |
| EP3973948B1 (en) | Cosmetic composition with combined filler and skin regenerative effect | |
| KR20160003269A (en) | Agent for treating skin aging | |
| EP2629764A1 (en) | Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose | |
| KR101917026B1 (en) | Cosmetic composition for skin wrinkle improvement and prevention | |
| Onwubu et al. | Biobased materials in skin rejuvenation | |
| Beatini et al. | “REAL LIFE” efficacy evaluation of a new hyaluronic acid gel suitable for deep hydration and fine wrinkles correction | |
| Pachuau et al. | Natural polymer-based nanocarriers for advanced cosmeceutical application | |
| JP2021072906A (en) | Coacervate hyaluronan hydrogel for use in dermal filler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20130430 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20150806 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20151217 |